Immuno-conjugates and methods for producing them
The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.
1. An isolated protein comprising an immunoglobulin heavy chain variable region (V H ) and an immunoglobulin light chain variable region (V L ), wherein at least one of the variable regions comprises at least two cysteine residues substituted at positions exposed to solvent within a framework region 1 (FR1), wherein: (i) the at least two cysteine residues consist of 2, 4, or 6 cysteine residues, (ii) if at least two of the cysteine residues are not conjugated to a compound then a disulphide bond is capable of forming within the FR1 between the cysteine residues; and (iii) if the V L comprises the at least two cysteine residues, they are substituted at any of Kabat positions L7 to L19, and if the V H comprises the at least two cysteine residues, they are substituted at any of Kabat positions H7 to H20.
2. The isolated protein of according to claim 1 comprising a compound conjugated to at least one of the cysteine residues, wherein the conjugated compound does not reduce binding of the isolated protein to an antigen.
3. The isolated protein according to claim 1 , wherein at least one of the variable regions comprises an N-terminal threonine residue or an N-terminal serine residue.
4. The isolated protein according to claim 3 additionally comprising a compound conjugated to the threonine or serine residue.
5. The isolated protein according to claim 1 , comprising a plurality of polypeptides each comprising an immunoglobulin heavy chain variable region (V H ) and an immunoglobulin light chain variable region (V L ), wherein:
(i) at least one of the polypeptides comprises a V H comprising a sequence set forth in SEQ ID NO: 111; and
(ii) at least another of the polypeptides comprises a V L comprising a sequence set forth in SEQ ID NO: 113,
wherein the V H of the polypeptide at (i) and the V L of the polypeptide at (ii) associate to form a Fv capable of specifically binding to tumour antigen TAG-72, and wherein at least one of the immunoglobulin variable regions comprises the at least two cysteine residue substitutions.
6. The isolated protein of claim 5 , wherein the isolated protein is a diabody, triabody, or tetrabody.
7. The isolated protein according to claim 1 , wherein the isolated protein comprises an N-terminal serine or threonine residue.
8. The isolated protein according to claim 1 , comprising a disulphide bond between the at least two cysteine residues.
9. The isolated protein according to claim 1 , wherein the at least two cysteine residues consist of 2 or 4 cysteine residues.
10. The isolated protein according to claim 9 , wherein the at least two cysteine residues consist of 2 cysteine residues.
11. The isolated protein according to claim 1 , wherein V L , Kabat positions are selected from the group consisting of: (i) L 7 and L 11 ; (ii) L 8 and L 11 ; (iii) L 8 and L 12 ; (iv) L 14 and L 17 ; and (v) L 13 and L 19 .
12. The isolated protein according to claim 1 , wherein the V H Kabat positions are selected from the group consisting of: (i) H 7 and H 10 ; (ii) H 13 and H 16 ; or (iii) H 12 and H 18 .
13. The isolated protein according to claim 1 , wherein both the immunoglobulin heavy chain variable region (V H ) and the immunoglobulin light chain variable region (V L ) comprise the at least two cysteine residue substitutions.
14. The isolated protein according to claim 1 , wherein the isolated protein is an avibody.
15. A composition comprising the isolated protein according to claim 1 and a pharmaceutically acceptable carrier.
16. A composition comprising the isolated protein according to claim 5 and a pharmaceutically acceptable carrier.
17. A method for producing a protein comprising a compound conjugated to at least one of the at least two cysteine residues, the method comprising:
(i) obtaining the protein of claim 1 ; and
(ii) conjugating a compound to at least one of the cysteine residues in FR1 of the polypeptide(s) to thereby produce the protein.
18. A method for producing a protein comprising a compound conjugated to a N-terminal serine or threonine residue, the method comprising conjugating a compound to at least one serine or threonine residue at the N-terminus of a polypeptide of the protein according to claim 7 to thereby produce the protein.
19. A method for localizing or detecting an antigen in a subject, said method comprising:
(i) administering to a subject the protein according claim 2 for a time and under conditions sufficient for the protein to bind to an antigen, wherein the conjugated compound is a detectable label; and
(ii) detecting or localizing the detectable label in vivo.
20. A method for detecting an antigen in a biological sample, the method comprising contacting the biological sample with the protein according to claim 1 for a time and under conditions sufficient for the protein to bind to the antigen and form a complex, and detecting the complex.